GlassScriptPhysician profile
John Charles Matocha
NPI 1689754632
$6,668.19
in general payments reported to CMS, 2019-2025
41 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,147 · 2020: $1,797 · 2021: $1,654 · 2022: $802 · 2023: $583 · 2024: $310 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,268.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $1,251.46 | 2019-2023 | |
| Novo Nordisk INC | $578.41 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $497.07 | 2019-2024 | Airsupra, Breztri |
| Amgen INC. | $493.42 | 2019-2025 | Repatha, Otezla, Otezla |
| Pfizer INC. | $449.75 | 2019-2024 | |
| Glaxosmithkline, LLC. | $401.31 | 2020-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Exact Sciences Corporation | $351.55 | 2023-2025 | Cologuard Collection Kit |
| Eisai INC. | $330.71 | 2020-2021 | |
| Allergan, INC. | $272.84 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $230.94 | 2019-2022 | |
| Bausch Health US, LLC | $211.36 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $160.68 | 2019-2023 | Belsomra, Steglatro, Steglujan |
| Abbvie INC. | $153.87 | 2021-2022 | |
| Esperion Therapeutics, INC. | $147.98 | 2020-2021 | |
| Endo Pharmaceuticals INC. | $118.50 | 2019-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Matocha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.